A Single Dose, Fed state, Crossover Replicate, Bioequivalence Study of Naproxen 500 mg/ Esomeprazole 20 mg modified-release tablets (Antibiotice S.A.) versus Vimovo® 500 mg/20 mg film coated tablets (Grunenthal GmbH)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508621-27-00

Acronym

NAESAIS 02/2023

Enrollment

Registered

2024-03-04

Start date

2024-03-05

Completion date

2024-04-30

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Romania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026